Läs upp
För närvarande kan tillfälliga driftstörningar drabba fass.se. Problemet felsöks för närvarande.

FASS logotyp
Receptbelagd

Peka på symbolerna och beteckningarna till vänster för en förklaring.

Kontakt

Sök apotek med läkemedlet i lager

Sök lagerstatus

SIMBRINZA

Miljöinformation
Receptstatus
Förmånsstatus
Novartis

Ögondroppar, suspension 10 mg/ml + 2 mg/ml
(Vit till benvit homogen suspension, ögondroppar)

Medel mot glaukom

Aktiva substanser (i bokstavsordning):
ATC-kod: S01EC54
Utbytbarhet: Utbytbara läkemedel
Läkemedel från Novartis omfattas av Läkemedelsförsäkringen.
Läkemedlet distribueras också av företag som inte omfattas av Läkemedelsförsäkringen, se Förpackningar.
  • Vad är miljöinformation?

Miljöinformation

Miljöpåverkan

Brimonidin

Miljörisk: Risk för miljöpåverkan av brimonidin kan inte uteslutas då ekotoxikologiska data saknas.
Nedbrytning: Det kan inte uteslutas att brimonidin är persistent, då data saknas.
Bioackumulering: Det kan inte uteslutas att brimonidin kan bioackumuleras, då data saknas.


Läs mer

Detaljerad miljöinformation

Environmental Risk Classification

Predicted Environmental Concentration (PEC)

PEC is calculated according to the following formula:

PEC (μg/L) = (A*109*(100-R))/(365*P*V*D*100) = 1.37*10-6 * A * (100 - R) = 1.37*10-6 * 2.46 kg * 100 = 0.000337 μg/L = 0.337 ng/L


Where:

A = 2.4595 kg (total sold amount API in Sweden year 2022, data from IQVIA).

R = 0 % removal rate (due to loss by adsorption to sludge particles, by volatilization, hydrolysis or biodegradation) = 0, if no data is available.

P = number of inhabitants in Sweden = 10 * 106

V (L/day) = volume of wastewater per capita and day = 200 (ECHA default) (ECHA 2008)

D = factor for dilution of waste water by surface water flow = 10 (ECHA default) (ECHA 2008).


Predicted No Effect Concentration (PNEC)

Ecotoxicological studies

Algae: no data available

Crustacean (Daphnia magna): no data available

Fish: no data available

Other ecotoxicity data: No data available

PNEC derivation:

No PNEC can be calculated since there is no environmental toxicity data available.


Environmental risk classification (PEC/PNEC ratio)

Calculation of a risk ratio is not possible, due to the lack of environmental toxicity data. Therefore, the following phrase is used: "Risk of environmental impact of brimonidin cannot be excluded, since no ecotoxicity data are available." According to the European Medicines Agency guideline on environmental risk assessment of medicinal products (EMA/CHMP/SWP/4447/00), use of brimonidin is unlikely to represent a risk for the environment, because the predicted environmental concentration (PEC) at the time of registration is below the action limit 0.01 μg/L.


Degradation

Biotic degradation

Ready degradability: no data available

Justification of chosen degradation phrase:

As no data on biological degradation is available, the following phrase is used: The potential for persistence of brimonidin cannot be excluded, due to lack of data.


Bioaccumulation

Partitioning coefficient:

No data available

Justification of chosen bioaccumulation phrase:

As no information on the octanol-water partition coefficient is available, the following statement is used for fluorescein: The potential for bioaccumulation of brimonidin cannot be excluded, due to lack of data.


Excretion (metabolism)

Following administration of brimonidine tartrate gel (1 g of gel containing 5 mg of brimonidine tartrate applied to the entire face) once daily for 29 days in patients with erythema associated with rosacea, peak plasma concentration and area under the concentration-time curve (AUC) were 40 and 20%, respectively, those observed following administration of brimonidine tartrate 0.2% ophthalmic solution (1 drop in each eye every 8 hours for 24 hours). Mean peak plasma concentration and AUC were highest on day 15 in patients receiving brimonidine gel. Systemic exposure was slightly lower on day 29, indicating no further drug accumulation with brimonidine gel application.

Brimonidine is extensively metabolized by the liver.1 Urinary excretion is the major route of elimination of brimonidine and its metabolites (Medicines Complete 2017).


References

Brinzolamid

Miljörisk: Risk för miljöpåverkan av brinzolamid kan inte uteslutas då ekotoxikologiska data saknas.
Nedbrytning: Det kan inte uteslutas att brinzolamid är persistent, då data saknas.
Bioackumulering: Brinzolamid har låg potential att bioackumuleras.


Läs mer

Detaljerad miljöinformation

Environmental Risk Classification

Predicted Environmental Concentration (PEC)

PEC is calculated according to the following formula:

PEC (μg/L) = (A*109*(100-R))/(365*P*V*D*100) = 1.37*10-6 * A * (100 - R) = 1.37*10-6 * 23.7 * 100 = 0.0032 μg/L


Where:

A = 23.6637 kg brinzolamide (total sold amount API in Sweden year 2021, data from IQVIA).

R = 0 % removal rate (due to loss by adsorption to sludge particles, by volatilization, hydrolysis or biodegradation) = 0, if no data is available.

P = number of inhabitants in Sweden = 10 *106

V (L/day) = volume of wastewater per capita and day = 200 (ECHA default) (ECHA 2008)

D = factor for dilution of waste water by surface water flow = 10 (ECHA default) (ECHA 2008)


Predicted No Effect Concentration (PNEC)

Ecotoxicological studies

Algae: no data available

Crustacean (Daphnia magna): no data available

Fish: no data available

Other ecotoxicity data: No data available

PNEC derivation:

No PNEC can be calculated since there is no environmental toxicity data available


Environmental risk classification (PEC/PNEC ratio)

Calculation of a risk ratio is not possible, due to the lack of environmental toxicity data. Therefore, the following phrase is used: "Risk of environmental impact of brinzolamide cannot be ruled out as ecotoxicological data are missing."


According to the European Medicines Agency guideline on environmental risk assessment of medicinal products (EMA/CHMP/SWP/4447/00), use of brinzolamide is unlikely to represent a risk for the environment, because the predicted environmental concentration (PEC) at the time of registration was below the action limit 0.01 μg/L.


Degradation

Biotic degradation

Ready degradability: no data available

Justification of chosen degradation phrase:

As no data on biological degradation is available the following phrase is used: ‘The potential for persistence of brinzolamide cannot be excluded, due to lack of data.’


Bioaccumulation

Partitioning coefficient:

logKow = 0.817 (method unknown) (Alcon Technical Report No. 136:60:0900)

Justification of chosen bioaccumulation phrase:

As log Kow < 4, the following statement is used for Brinzolamide: ‘Brinzolamide has low potential for bioaccumulation.’


Excretion (metabolism)

Following topical or systemic administration, brinzolamide undergoes metabolic reactions that include N-dealkylation, O-dealkylation and oxidation of the N-propyl side chain, all CYP-450 catalyzed reactions. N-desethyl brinzolamide is the major metabolite of brinzolamide in primates and human whole blood and is the only quantifiable metabolite in human whole blood. (Alcon Technical Report No. 025:38570:0596, Alcon Technical Report No. 027:38570:0596, Alcon Technical Report No. 029:38570:0596, Alcon Technical Report No. 037:38570:0796) Studies with radioactive 14C-brinzolamide revealed that after 24 hours following an IV does, that approximately 50-60% of brinzolamide was excreted unchanged from the body and that approximately 42% remained in the blood and the carcass. (Alcon Technical Report No. 014:38570:0496)


PBT/vPvB assessment

Based on screening information, brinzolamide cannot be considered a potential PBT substance as the octanol-water partition coefficient remains significantly below the trigger level for a bioaccumulative substance.


References


Upp